Top Abstract Purchase Related
Home
>
Node
>
Subnode

Rituximab in the treatment of diffuse large B-cell lymphomas

Coiffier, B.

Seminars in Oncology 29(1 Suppl 2: 30-35

2002

ISSN/ISBN: 0093-7754
PMID: 11842386
Document Number: 551608
A review of the use of rituximab (Rituxan; Genentech, Inc, South San Francisco, CA, and IDEC Pharmaceuticals, San Diego, CA) in diffuse large B-cell lymphomas is presented, focusing on the recent presentation of the combination of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) plus rituximab in elderly patients. This combination increased the response rates, event-free survival, and overall survival of patients older than 60 years in comparison with CHOP alone. The toxic events observed with the combination were not more numerous or severe than those observed with CHOP alone. Rituximab is a chimeric anti-CD20 antibody that increases the treatment options in patients with B-cell lymphomas.

Document emailed within 1 workday
Secure & encrypted payments

Zhang, H.-Y.; Guan, Z.-Z.; Wang, B.; Huang, H.-Q.; Xia, Z.-J.; Lin, T.-Y. 2008: Relationship between clinopathological features and outcome of rituximab treatment for diffuse large B-cell lymphoma Zhonghua Zhong Liu Za Zhi 30(5): 381-384
Angsirisak, N.; Wittayalertpanya, S.; Limpanasithikul, W.; Bunworasate, U.; Owattanapanich, D. 2015: Correlation of FcγRIIIa Polymorphisms to the Response of Rituximab in Thai Patients with Diffuse Large B-Cell Lymphoma Journal of the Medical Association of Thailand 98(12): 1215-1221
Bai, M.; Skyrlas, A.; Agnantis, N.J.; Kamina, S.; Papoudou-Bai, A.; Kitsoulis, P.; Kanavaros, P. 2005: B-cell differentiation, apoptosis and proliferation in diffuse large B-cell lymphomas Anticancer Research 25(1a): 347-362
Bauer, K.D.; Merkel, D.E.; Winter, J.N.; Marder, R.J.; Hauck, W.W.; Wallemark, C.B.; Williams, T.J.; Variakojis, D. 1986: Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas Cancer Research 46(6): 3173-3178
Manabe, M.; Hayashi, Y.; Yoshii, Y.; Mukai, S.; Sakamoto, E.; Kanashima, H.; Nakao, T.; Hayama, T.; Fukushima, H.; Inoue, T.; Yamane, T.; Teshima, H. 2012: Primary diffuse large B-Cell lymphoma of the prostate presenting with urinary retention and dyschezia for which rituximab-combined CHOP therapy was effective-a case presentation Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(11): 1733-1735
Straus, D.J.; Wong, G.; Yahalom, J.; Varsos, G.; Gulati, S.; Clarkson, B. 1991: Diffuse large cell lymphoma. Prognostic factors with treatment Leukemia 5(Suppl): 32-37
Magomedova, A.U.; Kravchenko, S.K.; Kremenetskaia, A.M.; Zvonkov, E.E.; Bariakh, E.A.; Margolin, O.V.; Kaplanskaia, I.B.; Vorob'ev, I.A.; Samoĭlova, R.S.; Obukhova, T.N.; Moiseeva, T.N.; Zybunova, E.E.; Gemdzhian, E.G.; Vorob'ev, A.I. 2006: The modified program NHL-BFM-90 in the treatment of patients with diffuse large B-cell lymphosarcoma Terapevticheskii Arkhiv 78(10): 44-47
Niitsu, N. 2012: Treatment of patients with relapsed or refractory diffuse large B-cell lymphoma Nihon Rinsho. Japanese Journal of Clinical Medicine 70(Suppl 2): 509-513
Liu, H.; Zhang, R.-p.; Li, F.-x.; Quan, J.-c.; Liang, H. 2013: Treatment and prognostic analysis of early stage of primary gastric diffuse large B-cell lymphoma Zhonghua Wei Chang Wai Ke Za Zhi 16(1): 36-39
Jacobs, P.; King, H.S.; Cassidy, F.; Dent, D.M.; Harrison, T. 1981: VP-16-213 in the treatment of stage III and IV diffuse lymphocytic lymphoma of the large cell (histiocytic) variety: an interim report Cancer Treatment Reports 65(11-12): 987-993
Skarin, A.T. 1986: Diffuse aggressive lymphomas: a curable subset of non-Hodgkin's lymphomas Seminars in Oncology 13(4 Suppl 5: 10-25
Coiffier, B. 1993: Prognostic factors in large-cell lymphomas Pathologie-Biologie 41(1): 92-93
Mosnier, J.F.; Molas, G.; Gay, D.; Loncle, T.; Hénin, D. 1993: Is it possible to individualize microvillous large-cell lymphoma among sinusoid lymphomas? Annales de Pathologie 13(5): 346-350
Leahu, S. 1980: The "large cell" malignant lymphomas. A retrospective morphological analysis Medecine Interne 18(3): 333-338
Papajik, T.; Raida, L.; Faber, E.; Vondrakova, J.; Prochazka, V.; Kubova, Z.; Skoumalova, I.; Jarosova, M.; M, L.K.; Paucek, B.; Myslivecek, M.; Neoral, C.; Oral, I.; Jarkovsky, J.; Dusek, L.; Indrak, K. 2008: High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission Neoplasma 55(3): 215-221
Guglielmi, C.; Amadori, S.; Ruco, L.P.; Mantovani, L.; Martelli, M.; Papa, G.; Mandelli, F. 1987: Combination chemotherapy for the treatment of diffuse aggressive lymphomas: F-MACHOP update Seminars in Oncology 14(2 Suppl. 1): 104-109
Eimpunth, S.; Sittinamsuwan, P.; Pattanaprichakul, P.; Silpa-archa, N.; Sethabutra, P.; Chularojanamontri, L.; Hanamornroongruang, S.; Mahaisavariya, P. 2012: Cutaneous anaplastic large cell lymphomas: a report of 9 cases from Thailand Journal of the Medical Association of Thailand 95(3): 437-443
Sharma, V.; Gupta, S.; Patel, M.; Dora, T.; Sancheti, S. 2018: Diffuse Large B Cell Lymphoma of Larynx Journal of the Association of Physicians of India 66(5): 91-93
Passoni, L.; Gallo, B.; Biganzoli, E.; Stefanoni, R.; Massimino, M.; Di Nicola, M.; Gianni, A.M.; Gambacorti-Passerini, C. 2006: In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas Haematologica 91(1): 48-55
Kreuziger, L.M.B.; Morrison, V.A. 2011: Late relapses in diffuse large B-cell lymphoma Clinical Advances in Hematology and Oncology: H&o 9(9): 709-710